Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

被引：0
|
作者：
Paul F. Schellhammer
Robert M. Hershberg
机构：
[1] Norfolk,Eastern Virginia Medical School and Devine Tidewater Urology
[2] Seattle,Dendreon Corporation
[3] 6333 Center Drive,Interstate Corporate Center
来源：
World Journal of Urology | 2005年 / 23卷
关键词：
Prostate cancer; Immunotherapy; Vaccine; Androgen independent; Provenge; Hormone refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.
引用
收藏
页码：47 / 49
页数：2
相关论文
共 50 条
  • [31] Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis - Reply
    不详
    JOURNAL OF UROLOGY, 2008, 179 (06): : 2196 - 2196
  • [32] Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era
    Oefelein, MG
    Ricchiuti, VS
    Conrad, PW
    Goldman, H
    Bodner, D
    Resnick, MI
    Seftel, A
    UROLOGY, 2002, 60 (01) : 120 - 124
  • [33] The potential for neurocognitive toxicity in the treatment of androgen-independent prostate cancer
    Garofalo, J.
    Heinige-Kenworthy, T.
    Beer, T.
    PSYCHO-ONCOLOGY, 2007, 16 (03) : S70 - S70
  • [34] Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis - Comment
    Morgentaler, Abraham
    Marks, Leonard S.
    JOURNAL OF UROLOGY, 2008, 179 (06): : 2195 - 2196
  • [35] Androgen-independent induction of prostate-specific antigen in prostate cancer cells by factors secreted from osteoblast-like cells.
    Kim, TSY
    Bruchovsky, N
    McAlinden, G
    Duncan, CP
    Jones, EC
    Schnabel, DD
    Schweikert, HU
    Sadar, MD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S336 - S336
  • [36] Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: A review
    Westin, P
    Bergh, A
    CANCER DETECTION AND PREVENTION, 1998, 22 (05): : 476 - 484
  • [37] Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells
    Hsieh, Chen-Lin
    Cai, Changmeng
    Giwa, Ahmed
    Bivins, Aaronica
    Chen, Shao-Yong
    Sabry, Dina
    Govardhan, Kumara
    Shemshedini, Lirim
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2008, 41 (1-2) : 13 - 23
  • [38] Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
    de Charette, Marie
    Marabelle, Aurelien
    Houot, Roch
    EUROPEAN JOURNAL OF CANCER, 2016, 68 : 134 - 147
  • [39] Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
    Beer, Tomasz M.
    Bernstein, Guy T.
    Corman, John M.
    Glode, L. Michael
    Hall, Simon J.
    Poll, Wayne L.
    Schellhammer, Paul F.
    Jones, Lori A.
    Xu, Yi
    Kylstra, Jelle W.
    Frohlich, Mark W.
    CLINICAL CANCER RESEARCH, 2011, 17 (13) : 4558 - 4567
  • [40] ANDROGEN INDEPENDENT, TUMOR-REINITIATING CELLS ARE SELECTED BY ANDROGEN DEPRIVATION IN MODELS OF ANDROGEN DEPENDENT PROSTATE CANCER
    Germann, Markus
    Wetterwald, Antoinette
    Guzman, Natalia
    Williams, Elizabeth
    Cecchini, Marco G.
    Thalmann, George N.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E110 - E110
12345